The effect of hemoadsorption to patients with Stanford Type A Aortic Dissection

To observe the effect of hemoadsorption, an emerging therapy potentially valuable in blood purification, inflammation inhibition and toxic removal, to patients with Stanford Type A Aortic Dissection.

The clinical data of 100 patients with TAAD from January 2021 to June 2023 were retrospectively analyzed. Patients were divided into HA group and CON group, depending on the usage of hemoadsorption during the cardiopulmonary bypass, with 50 patients in each group. The comparison between two groups was performed including cardiopulmonary time, surgery time, aortic cross-clamp time, deep hypothermia cardiac arrest time, ultrafiltration volume, urine output as well as blood transfusion and clinical laboratory tests such as white cell count, aspartate aminotransferase, alanine transaminase, creatinine as well as blood urea nitrogen. All these variables were measured at 24 h and 48 h after surgery.

There was no significant difference for both baseline characteristics and surgery-related variables between two groups (P > 0.05). The number of patients with ICU stay ≤ 6 d in HA group was higher significantly than that in CON group (P = 0.038), while, other remaining endpoints were not significant in two groups (P > 0.05). Postoperative 24 h and 48 h, lower aspartate aminotransferase and alanine transaminase are associated with intraoperative hemoadsorption (P = 0.006, 0.006, 0.001 and 0.001, respectively).

Hemoadsorption is correlated with early positive and favorable changes of laboratory tests.